These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

398 related items for PubMed ID: 26378637

  • 1. First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial.
    Chawla SP, Papai Z, Mukhametshina G, Sankhala K, Vasylyev L, Fedenko A, Khamly K, Ganjoo K, Nagarkar R, Wieland S, Levitt DJ.
    JAMA Oncol; 2015 Dec; 1(9):1272-80. PubMed ID: 26378637
    [Abstract] [Full Text] [Related]

  • 2. A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma.
    Chawla SP, Chua VS, Hendifar AF, Quon DV, Soman N, Sankhala KK, Wieland DS, Levitt DJ.
    Cancer; 2015 Feb 15; 121(4):570-9. PubMed ID: 25312684
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetic study of aldoxorubicin in patients with solid tumors.
    Mita MM, Natale RB, Wolin EM, Laabs B, Dinh H, Wieland S, Levitt DJ, Mita AC.
    Invest New Drugs; 2015 Apr 15; 33(2):341-8. PubMed ID: 25388939
    [Abstract] [Full Text] [Related]

  • 4. Aldoxorubicin for the treatment of soft tissue sarcoma.
    Sachdev E, Sachdev D, Mita M.
    Expert Opin Investig Drugs; 2017 Oct 15; 26(10):1175-1179. PubMed ID: 28846045
    [Abstract] [Full Text] [Related]

  • 5. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
    Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, Agulnik M, Cooney MM, Livingston MB, Pennock G, Hameed MR, Shah GD, Qin A, Shahir A, Cronier DM, Ilaria R, Conti I, Cosaert J, Schwartz GK.
    Lancet; 2016 Jul 30; 388(10043):488-97. PubMed ID: 27291997
    [Abstract] [Full Text] [Related]

  • 6. Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial.
    Tap WD, Wagner AJ, Schöffski P, Martin-Broto J, Krarup-Hansen A, Ganjoo KN, Yen CC, Abdul Razak AR, Spira A, Kawai A, Le Cesne A, Van Tine BA, Naito Y, Park SH, Fedenko A, Pápai Z, Soldatenkova V, Shahir A, Mo G, Wright J, Jones RL, ANNOUNCE Investigators.
    JAMA; 2020 Apr 07; 323(13):1266-1276. PubMed ID: 32259228
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
    Toma S, Tucci A, Villani G, Carteni G, Spadini N, Palumbo R.
    Anticancer Res; 2000 Apr 07; 20(1B):485-91. PubMed ID: 10769710
    [Abstract] [Full Text] [Related]

  • 10. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
    Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG, Radford JA, Van Glabbeke MM, Kirkpatrick A, Hogendoorn PC, Blay JY, European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
    J Clin Oncol; 2007 Jul 20; 25(21):3144-50. PubMed ID: 17634494
    [Abstract] [Full Text] [Related]

  • 11. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay JY, Kerst JM, Sufliarsky J, Whelan J, Hohenberger P, Krarup-Hansen A, Alcindor T, Marreaud S, Litière S, Hermans C, Fisher C, Hogendoorn PC, dei Tos AP, van der Graaf WT, European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Lancet Oncol; 2014 Apr 20; 15(4):415-23. PubMed ID: 24618336
    [Abstract] [Full Text] [Related]

  • 12. A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial.
    Karch A, Koch A, Grünwald V.
    Trials; 2016 Jul 07; 17(1):312. PubMed ID: 27387325
    [Abstract] [Full Text] [Related]

  • 13. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
    Le Cesne A, Blay JY, Domont J, Tresch-Bruneel E, Chevreau C, Bertucci F, Delcambre C, Saada-Bouzid E, Piperno-Neumann S, Bay JO, Mir O, Ray-Coquard I, Ryckewaert T, Valentin T, Isambert N, Italiano A, Clisant S, Penel N.
    Lancet Oncol; 2015 Mar 07; 16(3):312-9. PubMed ID: 25680558
    [Abstract] [Full Text] [Related]

  • 14. First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study.
    Demetri GD, Le Cesne A, Chawla SP, Brodowicz T, Maki RG, Bach BA, Smethurst DP, Bray S, Hei YJ, Blay JY.
    Eur J Cancer; 2012 Mar 07; 48(4):547-63. PubMed ID: 22240283
    [Abstract] [Full Text] [Related]

  • 15. Aldoxorubicin in soft tissue sarcomas.
    Chamberlain FE, Jones RL, Chawla SP.
    Future Oncol; 2019 May 07; 15(13):1429-1435. PubMed ID: 30873850
    [Abstract] [Full Text] [Related]

  • 16. Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas.
    Gong J, Yan J, Forscher C, Hendifar A.
    Drug Des Devel Ther; 2018 May 07; 12():777-786. PubMed ID: 29670334
    [Abstract] [Full Text] [Related]

  • 17. First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours.
    Schöffski P, Delord JP, Brain E, Robert J, Dumez H, Gasmi J, Trouet A.
    Eur J Cancer; 2017 Nov 07; 86():240-247. PubMed ID: 29055839
    [Abstract] [Full Text] [Related]

  • 18. A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: the TRUSTS trial.
    Bui-Nguyen B, Butrynski JE, Penel N, Blay JY, Isambert N, Milhem M, Kerst JM, Reyners AK, Litière S, Marréaud S, Collin F, van der Graaf WT, European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC/STBSG) and the Sarcoma Alliance for Research through Collaboration (SARC).
    Eur J Cancer; 2015 Jul 07; 51(10):1312-20. PubMed ID: 25912752
    [Abstract] [Full Text] [Related]

  • 19. Spotlight on aldoxorubicin (INNO-206) and its potential in the treatment of soft tissue sarcomas: evidence to date.
    Cranmer LD.
    Onco Targets Ther; 2019 Jul 07; 12():2047-2062. PubMed ID: 30936721
    [Abstract] [Full Text] [Related]

  • 20. Aldoxorubicin therapy for the treatment of patients with advanced soft tissue sarcoma.
    Seetharam M, Kolla KR, Ganjoo KN.
    Future Oncol; 2018 Oct 07; 14(23):2323-2333. PubMed ID: 29869517
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.